Table 5.
Multivariate analysis of graft versus host disease
| cGVHD | aGVHD grades II-IV | |
|---|---|---|
| Age (10-y increase) | 0.97 (0.85-1.1), P = .6249 | 0.93 (0.81-1.08), P = .3388 |
| Cytogenetic risk: poor vs intermediate | 0.79 (0.59-1.05), P = .1072 | 0.97 (0.71-1.33), P = .8714 |
| Year of HCT (1-y increase) | 0.99 (0.95-1.03), P = .4605 | 1.04 (0.99-1.09), P = .0902 |
| Female donor to male patient vs other | 1.29 (0.96-1.73), P = .0939 | 1.15 (0.81-1.64), P = .4243 |
| URD 10/10 vs MSD | 1.14 (0.82-1.59), P = .4232 | 1.45 (0.97-2.16), P = .0697 |
| URD 9/10 vs MSD | 0.88 (0.53-1.46), P = .6092 | 1.81 (1.08-3.05), P = .024 |
| CMV patient: positive vs negative | 0.96 (0.72-1.29), P = .8033 | 1.09 (0.78-1.52), P = .6232 |
| CMV donor: positive vs negative | 1.08 (0.83-1.4), P = .5887 | 1.12 (0.82-1.52), P = .4789 |
| Cell source: PB vs BM | 1.06 (0.68-1.65), P = .8041 | 1.21 (0.71-2.05), P = .4805 |
| Disease status at HCT: CR2 vs CR1 | 0.96 (0.53-1.73), P = .8827 | 1.06 (0.57-1.96), P = .851 |
| Disease status at HCT: active vs CR1 | 1.2 (0.92-1.57), P = .1753 | 1.09 (0.8-1.48), P = .5787 |
| TCD: ATG/alemtuzumab vs none | 0.55 (0.4-0.76), P = .0003 | 0.67 (0.45-0.98), P = .0369 |
| RIC vs MAC (overall effect) | 1.49 (1.11-2), P = .0075 | 0.83 (0.6-1.14), P = .2533 |